Supernus Pharmaceuticals Inc

NASDAQ:SUPN   3:59:32 PM EDT
31.87
-0.10 (-0.31%)
Products, Regulatory

Supernus Pharmaceuticals Says Co, Newron Received Notice Letters From MSN, Optimus & Zenara

Published: 05/19/2021 20:41 GMT
Supernus Pharmaceuticals Inc (SUPN) - Supernus Pharmaceuticals - on Each of May 14, May 15, & May 17, 2021, Co, Newron Received Notice Letters From Msn, Optimus & Zenara, Respectively.
Supernus Pharmaceuticals - Notice Letters Advised Co, Newron of Andas by Msn, Optimus, Zenara to FDA Seeking Approval for Safinamide Mesylate Tablets.
Supernus Pharmaceuticals - Notice Letters Directed to Three Xadago Patents That Expire Between June 2027 and December 2028.
Supernus Pharmaceuticals - Currently Reviewing Details of Notice Letters With Its Partners.